Latest news

• J&J’s ponesimiod tops Aubagio in head-to-head MS trial

  market-leading Tecfidera (dimethyl glutamate) and new injectables like Roche’s Ocrevus(ocrelizumab) also making strong headway in the market.

• Merck takes evobrutinib for MS into phase 3, on mixed data

  It will also have to contend with newer drugs like Roche’s fast-growing  Ocrevus(ocrelizumab), Novartis’  Mayzent(siponimod) and potentially Biogen’s Tecfidera follow-up  diroximel fumarate(BIIB098).

• Novartis scores promising phase 3 MS study

  It seems that Novartis is continuing to stake a claim in the MS therapy area, but will have to battle hard with competitors, including Roche’s blockbuster MS drug ocrevus. ... Ocrevus is also the only drug approved for the treatment of primary

• Lilly’s Levi Garraway will replace Sandra Horning as Roche CMO

  He will be tasked with adding to Roche’s growth products, like Ocrevus for multiple sclerosis and Hemlibra for haemophilia, with a string of 16 new molecular entity (NME) candidates in

• New products help lift Roche outlook despite biosimilar onslaught

  Roche powered through this decline thanks to Ocrevus (ocrelizumab) for multiple sclerosis which grew 63% to 1.7bn Swiss Francs ($1.7bn) for the first half of the year, and Hemlibra